Bortezomib 2 Mg Injection Suppliers & Bulk Manufacturers
Available Forms: Injection (lyophilized powder for solution)
Available Strengths: 1 mg/vial, 3.5 mg/vial, 2 mg
Reference Brands: Velcade® (US & EU), Bortecad (India)
Category:
Oncology Cancer Care
Bortezomib Injection is a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma, available in 1 mg and 3.5 mg vials in the US and EU.
Bortezomib 2 mg Injection is available in Injection (lyophilized powder for solution)
and strengths such as 1 mg/vial, 3.5 mg/vial, 2 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Bortezomib 2 mg Injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Bortezomib 2 mg Injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Bortezomib Injection, available in 1 mg and 3.5 mg lyophilized vials, is a leading oncology drug used for multiple myeloma and mantle cell lymphoma in the EU and US markets. As a proteasome inhibitor, Bortezomib disrupts protein degradation in cancer cells, inducing apoptosis and inhibiting tumor growth. Marketed under the brand Velcade®, this essential anticancer agent is available for IV and subcutaneous use. GMP-compliant manufacturers supply Bortezomib as a sterile injectable formulation, making it a high-demand product for pharmaceutical B2B sourcing, licensing, and global distribution in regulated markets.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing